| Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients M Van Kranenburg, M Magro, H Thiele, S de Waha, I Eitel, A Cochet, ... JACC: Cardiovascular Imaging 7 (9), 930-939, 2014 | 392 | 2014 |
| Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated … M Toubeau, C Touzery, P Arveux, G Chaplain, G Vaillant, A Berriolo, ... Journal of Nuclear Medicine 45 (6), 988-994, 2004 | 248 | 2004 |
| In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic … L Berthet, A Cochet, S Kanoun, A Berriolo-Riedinger, O Humbert, ... Journal of Nuclear Medicine 54 (8), 1244-1250, 2013 | 216 | 2013 |
| [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy A Berriolo-Riedinger, C Touzery, JM Riedinger, M Toubeau, B Coudert, ... European journal of nuclear medicine and molecular imaging 34, 1915-1924, 2007 | 203 | 2007 |
| 18F-FDG PET/CT for staging and restaging of breast cancer D Groheux, A Cochet, O Humbert, JL Alberini, E Hindié, D Mankoff Journal of Nuclear Medicine 57 (Supplement 1), 17S-26S, 2016 | 200 | 2016 |
| Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma S Kanoun, C Rossi, A Berriolo-Riedinger, I Dygai-Cochet, A Cochet, ... European journal of nuclear medicine and molecular imaging 41, 1735-1743, 2014 | 180 | 2014 |
| Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma S Kanoun, I Tal, A Berriolo-Riedinger, C Rossi, JM Riedinger, ... PloS one 10 (10), e0140830, 2015 | 120 | 2015 |
| Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes O Humbert, A Berriolo-Riedinger, JM Riedinger, B Coudert, L Arnould, ... Annals of oncology 23 (10), 2572-2577, 2012 | 112 | 2012 |
| 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations A Cochet, I Dygai-Cochet, JM Riedinger, O Humbert, A Berriolo-Riedinger, ... European journal of nuclear medicine and molecular imaging 41, 428-437, 2014 | 91 | 2014 |
| Major prognostic impact of persistent microvascular obstruction as assessed by contrast-enhanced cardiac magnetic resonance in reperfused acute myocardial infarction AA Cochet, L Lorgis, A Lalande, M Zeller, JC Beer, PM Walker, C Touzery, ... European radiology 19, 2117-2126, 2009 | 87 | 2009 |
| Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer A Cochet, G Quilichini, I Dygai-Cochet, C Touzery, M Toubeau, ... Breast cancer research and treatment 130, 845-854, 2011 | 79 | 2011 |
| Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer O Humbert, JM Riedinger, C Charon-Barra, A Berriolo-Riedinger, ... Clinical Cancer Research 21 (24), 5460-5468, 2015 | 77 | 2015 |
| HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy O Humbert, A Cochet, JM Riedinger, A Berriolo-Riedinger, L Arnould, ... European journal of nuclear medicine and molecular imaging 41, 1525-1533, 2014 | 77 | 2014 |
| Emidec: a database usable for the automatic evaluation of myocardial infarction from delayed-enhancement cardiac MRI A Lalande, Z Chen, T Decourselle, A Qayyum, T Pommier, L Lorgis, ... Data 5 (4), 89, 2020 | 76 | 2020 |
| Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors A Cochet, S Pigeonnat, B Khoury, JM Vrigneaud, C Touzery, ... Journal of Nuclear Medicine 53 (4), 512-520, 2012 | 76 | 2012 |
| Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer O Humbert, A Berriolo-Riedinger, A Cochet, M Gauthier, C Charon-Barra, ... European journal of nuclear medicine and molecular imaging 41, 416-427, 2014 | 74 | 2014 |
| Role of positron emission tomography for the monitoring of response to therapy in breast cancer O Humbert, A Cochet, B Coudert, A Berriolo-Riedinger, S Kanoun, ... The oncologist 20 (2), 94-104, 2015 | 71 | 2015 |
| Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? G Crehange, M Roach III, E Martin, L Cormier, D Peiffert, A Cochet, ... Cancer/Radiothérapie 18 (5-6), 524-534, 2014 | 60 | 2014 |
| The extent of myocardial damage assessed by contrast‐enhanced MRI is a major determinant of N‐BNP concentration after myocardial infarction A Cochet, M Zeller, Y Cottin, C Robert‐Valla, A Lalande, I L'Huilllier, ... European Journal of Heart Failure 6 (5), 555-560, 2004 | 53 | 2004 |
| French ccAFU guidelines-update 2020-2022: prostate cancer F Rozet, P Mongiat-Artus, C Hennequin, JB Beauval, P Beuzeboc, ... Progres en Urologie: Journal de L'association Francaise D'urologie et de la …, 2020 | 52 | 2020 |
